Wednesday, 6th July 12pm (AEST)
Hear from a selection of CEOs who provide a succinct overview of big things their companies are doing, followed by an interactive Q&A.
This week we are joined by:
- (ASX: PCK) PainChek Limited – a global healthcare tech company with a dominant 60% market share in Australia and an accelerating presence in the UK and New Zealand.
- (ASX: EGL) Environmental Group Limited – an under-the-radar group of environmentally focused companies positioned to capitalise on the fast-growing, US$4 trillion-plus ‘green economy’
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
CEO - PainChek Limited (ASX: PCK)
PainChek is an Australian healthcare tech company and developer of the world’s first smart device-based pain assessment and monitoring application for infants and adults. The company’s SaaS AI platform is contracted to 126,000 patient beds across 1500 facilities globally, claiming a dominant 60% market share in Australia. In the year to March 2022, PainChek has shown consistent growth in customer revenue, contracted beds and subscriptions – demonstrated by its $3.2 million in ARR. The company is positioned to capture a near $1.3 billion global market opportunity spanning ANZ, Europe, the US, Canada, Japan and Singapore, leading up to FY24.
CEO - Environmental Group Limited (ASX: EGL)
EGL has five business units focused on improving air and water quality, reducing carbon emissions and enhancing waste treatment – including a contract with the largest waste recycling plant in the southern hemisphere. The group operates within the ‘green economy’ – a US$4 trillion-plus industry comprising 5.4% of the total value of global listed equities. As at H1 FY22, EGL has seen steady growth in revenue (11.5%), EBITDA (28%) and NPAT (244%) on its H1 FY21 performance, along with a 247% increase in its share price from 30th June 2021. Fund manager Harley Grosser considers the stock to be cheap and under-the-radar for its underappreciated growth prospects, catalytic earnings strength and more.